Emerging and potential therapies for osteoporosis.

about

Lactoferrin--a novel bone growth factor Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman Effects of OsteoKing on osteoporotic rabbits The functional mechanism of simvastatin in experimental osteoporosis.

P2860

Q33218791-1EAB0B2F-DC67-4E91-ABAE-7A9AB1B9DCCE Q33346629-0024BBB2-A0E6-4AD8-8EDD-2BEDBA4264A7 Q35628178-B65A202A-9759-4923-AE86-0760060C3B3B Q53667928-64112853-FC35-46E8-A475-F1E2D210D620

P2860

Emerging and potential therapies for osteoporosis.

Item

http://www.wikidata.org/entity/Q36099415

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Emerging and potential therapies for osteoporosis.

@ast

Emerging and potential therapies for osteoporosis.

@en

type

Item

label

Emerging and potential therapies for osteoporosis.

@ast

Emerging and potential therapies for osteoporosis.

@en

prefLabel

Emerging and potential therapies for osteoporosis.

@ast

Emerging and potential therapies for osteoporosis.

@en

P1476

Emerging and potential therapies for osteoporosis.

@en

P2093

Andrew Grey

http://www.w3.org/2001/XMLSchema#string

Ian R Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]

The role of statins as potential targets for bone formation

P304

265-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.14.3.265

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15833058

http://www.w3.org/2001/XMLSchema#string

Emerging and potential therapies for osteoporosis.

about

P2860

P2860

Emerging and potential therapies for osteoporosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698